Superior vena cava syndrome results from the obstruction of blood flow through the superior vena cava and is most often due to thoracic malignancy. However, benign etiologies are on the rise secondary to more frequent use of intravascular devices such as central venous catheters and pacemakers. Although rarely a medical emergency, the symptoms can be alarming, particularly to the patient. Traditionally, superior vena cava syndrome has been managed with radiotherapy and chemotherapy. But interventional endovascular techniques have made inroads that offer a safe, rapid, and durable response. In many cases, it may be the only reasonable treatment. Because of this, an approach to endovascular treatment of this condition must be in the armamentarium of the interventional radiologist. This review will provide the reader with an insight into the etiology, pathophysiology, and various management principles of superior vena cava syndrome. The focus will be on understanding the techniques used during various endovascular interventions, including angioplasty, stenting, and pharmacomechanical thrombolysis. Discussion will also be centred on possible complications and current evidence as well as controversies regarding these approaches.
of infection-associated SVCS. Over the past 30 years, malignancy has become the leading cause of SVCS. However, the increasing use of central venous catheters and other intravascular devices has been responsible for a rise in the number of SVCS not related to malignancies [1] .
Still today, SVCS related to a neoplastic cause remains most prevalent [3, 4] . Carcinoma of the bronchus is the most common malignancy associated with SVCS. It is more common with squamous cell lung carcinoma [4] . Other malignancies that are associated with SVCS are lymphoma, metastatic disease, thymoma, and mesothelioma, to name a few [4] . Any tumour that involves the anterior or middle mediastinum and nodal enlargement in the right paratracheal and precarinal region can be associated with obstruction of the SVC [5] . The tumour can obstruct the SVC by compressing it directly or through nodal enlargement. Direct invasion has also been described [2] .
Nonmalignancy-related causes of SVCS, excluding infectious causes, have been on the rise for the past 25 years. This is primarily due to complications associated with the increasing use of various intravascular devices, such as venous catheters and pacemakers [2] . Rossi et al [6] found that 25% of patients with pacemakers had central venous obstruction or stenosis despite only 1%-3% being symptomatic, which is presumably due to good collateral pathways. In their series, symptoms were apparent 1-15 months after the insertion of the pacemaker [6] . There also are other rare nonneoplastic diseases that can cause SVCS, for example, fibrosing mediastinitis, which is a rare chronic inflammatory condition similar to retroperitoneal fibrosis [7] and clinically manifests in 60% of the cases secondary to compression of mediastinal structures, particularly the SVC.
Clinical Presentation
Onset and severity of symptoms are related to the rapidity of the obstruction of the SVCS and establishment of collaterals. The stenosis or occlusion can extend to involve the brachiocephalic veins. Patients can present with a wide range of symptoms. The most common symptoms are facial and neck swelling (82%), upper limb swelling (68%), dyspnea (66%), cough (50%), and dilated veins (38%) [2, 5] . These symptoms are more prevalent when the patient lies supine, with variable degrees of relief when the patient sits upright. If symptoms develop over weeks or months, collateral pathways can form. The most important collateral pathway is via the azygos vein. The symptoms are more severe if the level of obstruction is below the azygos vein [5, 8] .
Although the onset of symptoms can be alarming to both the patient and relatives, it is rarely fatal. There are at least 2 scoring systems that stratify the severity of SVCS [9, 10] . Although these are unvalidated, they do provide a useful system of stratifying the disease and creating a framework for triaging and managing these patients. Patients who fall into categories 3 and 4 of the classification system proposed by the Yale group, as defined by the presence of laryngeal oedema, cerebral oedema (headaches and dizziness), or diminished cardiac reserve (postural syncope), will require emergent treatment [5, 10] . Treatment options include chemotherapy, radiotherapy, surgery, and percutaneous intravascular procedures. Before embarking on a chemo-or radiotherapy regimen, a diagnosis should be reached with imaging and histologic confirmation, because these treatments can affect the ability of obtaining good histologic quality tissue, which can dictate further management. Every case, therefore, should be discussed at multidisciplinary meetings to ensure that the optimum treatment is instituted.
The Role of Interventional Radiology in Managing SVCS
Since the first report of stenting of a SVCS in 1986, endovascular treatment has become an established treatment option for managing SVCS [11] . Before stenting, chemotherapy, radiotherapy, and, at times, steroid administration were routinely used. Although they still play a role, they are limited by the fact that the tumour must be sensitive to these modality. Also, none offer immediate relief and can even make symptoms transiently worse during the inflammatory phase of the treatment. In addition, certain chemotherapeutic agents, for example, cisplatin, require the patient to be hydrated, which could also worsen the patient's symptoms. Stenting can be useful when urgent intervention is required and there is no tissue diagnosis or there has been a poor response to chemotherapy and radiotherapy. As always, case selection is of vital importance to ensure that the appropriate treatment is selected for each patient. Generally, in patients with a good chance of recovery and those with benign disease with a longer life expectancy, stenting should be avoided because stent occlusion is likely to eventually occur [4] . The added benefit of endovascular treatment is that it does not interfere with subsequent tissue sampling and further definitive treatment.
Although there are no randomized control studies to firmly establish the role of endovascular stenting, there are numerous cases studies that have demonstrated benefit accrued from their usage [9,12e40] . A review of English medical literature identified 10 studies that have a patient population of more than 50 [12e19, 34, 36] . These have been summarized in Table 1 . In addition to stenting and angioplasty, thrombolysis can be undertaken to dissolve soft thrombus and further facilitate opening of the lumen and subsequent stent deployment [12,41e46] .
Endovascular Technique
Initial venographic assessment is mandatory to plan treatment, which includes deciding on the length and number of stents required. If possible, this assessment should be obtained at a different sitting than that of the actual treatment. It is best obtained via traditional venographic studies by injecting contrast, under fluoroscopy, into the veins of both arms, which allows the best delineation of the stenotic segment and the presence of intraluminal filling defects that would suggest clot as a component of the syndrome. It also allows assessment of the direction of flow in the collateral veins, such as the azygos. However, computed tomographic venography has the advantage of better demonstrating the cause of the SVCS and better determining the inferior extent of the lesion when it is completely occlusive. Therefore, both approaches have value.
The treatment is generally performed with the patient under local anaesthetic in the angiographic suite and, rarely, with conscious sedation, if needed. When conscious sedation is used, due to the general frailty of these patients, it requires regular observation by a dedicated member. Resuscitation equipment should be within close reach. If respiratory distress is a symptom of the SVCS, then the patient may have to be placed with his or her head partially elevated. For nonocclusive lesions, a single access point may be sufficient, but, when there is complete occlusion, it is useful to have an access point from above and from below, usually via punctures of both the internal jugular and common femoral veins, which allows obtaining a precise venographic study to define the exact length of the occlusion by injecting contrast both above and below the occlusion. As well, it provides an intravascular guide to orient the recanalization maneuver with more safety. Also, it allows exiting the wire, once it has passed through the stenosis, from both sites, hence creating a strong and stable scaffold over which the angioplasty balloons can be advanced and the stents deployed safely. If only a single access point must be used, then our group prefers using an access via the right common femoral vein. The advantage we see in this is that, during the deployment of self-expanding stents, by releasing the superior part of the stent first, the operator can have a feel of the stability of the stent before complete deployment, which we believe may help decrease the risk of stent migration towards the heart. However, this is simply our personal experience, and many other access points have been described, including via the internal jugular, basilic, and subclavian veins, with good success and good safety profile. Nicholson et al [34] recommended the subclavian approach albeit with an increased risk of a pneumothorax. Ganeshan et al [26] reported the regular use of the internal jugular vein as an access. Once a wire has successfully crossed through the stenosis, angioplasty or stenting can be performed over the wire (Figures 1 and 2 ). Operators should try and ensure that the tip of the guidewire be advanced far beyond the stenosis, such as in the inferior vena cava for a jugular approach or an arm vein for a femoral approach. This ensures that, if stent migration occurs, particularly into the heart, then the stent remains safely around the wire, and additional stents can be placed or a rendezvous technique performed for snaring and safe removal of the stent.
When there is complete occlusion, various maneuvers can be used to recanalize the vein, including the use of stiff wires and straight catheters. Sharp recanalization (by using a 19-gauge trocar or a 22-gauge Chiba needle) or the use of the stiff back end of the guidewire has been used to cross difficult occlusions. These have been described for venous occlusions [47, 48] . However, such maneuvers, particularly the use of the stiff end of a guidewire, are off-label and should be undertaken only by a skilled operator because they are difficult to control and can lead to complications that can be life threatening. When recanalization is not possible with traditional techniques, the occlusion can be traversed with a radiofrequency wire. There are increasing numbers of reports in the literature that demonstrate the safety and efficacy of these wires in crossing venous occlusions [49e51]. When such aggressive measures are used, it is imperative to have a target placed on the other side of the stenosis to guide the direction of the recanalization, which can take the form of a catheter or snare placed on the opposite side of the stenosis (Figure 3 ). Three-dimensional rotational fluoroscopy images can also be performed to help guide the procedure by providing computed tomographicelike 3-dimensional images, albeit at the expense of radiation dose. Endovascular ultrasound may also be helpful to guide sharp recanalizations. However, there are still few data that confirm the usefulness of these alternate imaging modalities.
Care should be taken during angioplasty to prevent venous rupture, which can precipitate pericardial tamponade [4] . Fagedet et al [13] found the only statistically significant risk factor that led to complications was the use of stents larger than 16 mm in diameter. Similarly, a perforation of the SVC during the attempt at crossing an occlusion can also lead to tamponade, especially if the perforation occurs in the lower half of the SVC, which is the pericardium-covered portion [52] . Because of this serious risk, such procedures should not be undertaken if the operator is not comfortable in placing a pericardial drain.
Endovascular Stenting
A wide range of stents have been used in relieving SVCS, many not officially approved for use in the vascular system. The vast majority of them are uncovered stents, which are of 2 types: self-expanding and balloon expanding. The most commonly used self-expanding stent is the Wallstent (Boston Scidentific, Natick, MA). Other varieties that have been used are the [53, 54] . The Gianturco stents were used extensively in the initial reports [11, 24, 26, 29, 30, 55] , but now mostly Wallstents are used in managing SVCS. The Gianturco stent is rigid. However, its short length meant that multiple stents would be needed for long occlusions, which can be technically challenging [24, 26] . Also, their rigidity would make it difficult to negotiate deployment around curved vessels. The Wallstent, however, is longer and more flexible, which makes it easier to deploy, particularly in curved vessels. The main drawback of the Wallstent is the foreshortening and migrations that occur when it is deployed, which can make it unpredictable. However, stent migration can be reduced by careful planning and selection [56] . The stenosis should be covered with at least 1 cm free both proximal and distal to the lesion [4] . Over a wire, angioplasty is performed by using a 14-mm balloon. In this case, the catheter was not removed before angioplasty for access-site preservation reasons. However, it most often is, in which case, the access used for the angioplasty is through the tract of the removed catheter. (C) Postangioplasty venogram, demonstrating restoration of SVC luminal calibre, which was associated with immediate subjective improvement in patient symptoms.
Balloon-mounted stents, such as Palmaz (Cordis) stents, are used when precise placement is desired. Although they have high radial strength upon deployment, their compressibility can lead to reocclusion. The short length of a Palmaz stent can be used for accurate positioning in short stenosis. Either way, the stent should be 15%-20% larger than the vein being stented [14] . The choice of stent depends on the size, location, length of the lesion, and operator experience.
A review of the literature has identified 2 reports of primary stenting of the SVC by using a covered sent. Dendo et al [32] used polytetrafluoroethylene covered Z-stents (Cook Medical Inc) to relieve SVCS secondary to malignancy, and Gwon and Paik [37] used a stent graft (Vascular ComVi stent graft; TaeWoong Medical, Gimpo, Korea) in 2 of their patients with a similar background. Chin et al [33] used a covered stent during a reintervention, after the first uncovered stent was overwhelmed by tumour. Covered stents are also used in an emergency setting, when vessel perforation occurs during venoplasty. The perceived advantage of a covered stent is that it can prevent tumour ingress. Our limited experience in using covered stents in SVCS caused by malignant neoplasms is that the presumed increased time to occlusion has not always been impressive and remains to be proven. Either way, given the patient's often short life expectancy in these cases, it is questionable whether this is to be an issue. As well, the cost of a covered stent is higher.
Stenting can also relieve SVCS secondary to benign causes, particularly those related to the use of intravascular devices. In a recent review of SVCS in patients with pacemakers, Riley et al [31] compared 5 treatment modalities (anticoagulation, thrombolysis, venoplasty, stent, and surgery). There was low recurrence rate in the stent group when compared with the other treatment options. However, as the researchers observed, most of the studies had small numbers, and this, in itself, would predispose to reporting bias and underreporting of complications and treatment failures. Although not statistically significant, Rizvi et al [35] found a trend towards increased primary patency and less re-interventions in a patient treated for SVCS secondary to central line usage when compared with mediastinal fibrosiserelated cases. It is our belief that the use of stenting in cases of SVCS due to nonmalignancy-related causes should be reserved for patient, in whom angioplasty has failed, due to the risk of stent occlusion. However, there are no good studies that compared the primary and secondary patency rates in this cohort of patients. The value and safety of devices such as cutting balloons still remain to be adequately established. There is limited experience in the uses of cryotherapy for venous stenosis [57, 58] . In dealing with stenting, central venous catheters should be removed and reinserted after endovascular treatment of SVCS, if possible.
However, there is no consensus regarding patients with SVCS and with pacemakers, especially whether the pacemakers should be removed before stenting. In patients with such pacemaker wires, stent placement should be considered only in patients with complications or those with elastic recoil, stenosis, or recurrence [59] . In fact, Zartner et al [60] removed the pacemaker wire only if they were unusable, had reduced parameters, complete vessel occlusion, or if stent placement was required. But, if the leads were jailed by a stent, then there was no increased risk of thrombosis, and, in fact, Riley et al [31] thought that their removal would pose a greater risk. The choice of stents used in patients with pacemaker wires included both balloon-mounted and self-expanding stents [31, 59, 60] .
As discussed earlier, occlusion or thrombosis can extend to involve both the brachiocephalic veins in addition to the SVC. Although some interventionalists would prefer to undertake bilateral stenting, results of studies have shown this to be associated with increased complications, such as both stents obstructing each other and leading to thrombosis [17, 18, 34] . Unilateral stenting will usually relieve the SVC obstruction via recanalization of one brachiocephalic vein, with the other vein normally draining sufficiently via collaterals to the patent side.
Thrombolysis
The presence of soft thrombus in an occlusion should prompt attempts to relieve the clot burden before deciding to treat more aggressively. The presence of a thrombus should be considered in patients with acute onset of symptoms, occlusions that can easily be traversed by a wire, and when SVCS are secondary to central venous catheters [22] . In these patients, a trial of systemic anticoagulation or, in the acute setting, thrombolysis can be attempted by using thrombolytic agents delivered at the site of the clot through a catheter, which allows more effective local action. Reports of systematic administration of thrombolytic agents have also been described [43] . By reducing the thrombus load, the length of the obstruction can often be reduced, thus reducing the number of stents needed. Also, it permits incremental stent expansion to greater diameters than in an occluded vein [12] .
However, thrombolysis is most effective if it is started within 2-5 days of onset of symptoms and tends to be ineffective if started after 10 days [44] . Gray et al [41] found that 88% of the cases had a successful outcome when thrombolytic treatment was commenced within 5 days. The success rate dropped to 25% when it was started after 5 days [41] . They also observed that catheter-related SVCS demonstrated a better response to thrombolysis, which was attributed to the earlier detection of symptoms secondary to catheter dysfunction, the absence of extrinsic compression, and the ability to infuse the thrombolytic agent directly to the site of the thrombus via the existing catheter [41] . Caution should be exercised in patients with cystic fibrosis because an increased risk of hemoptysis and gastrointestinal bleeding has been reported in this patient population [43] .
Newer techniques that use pharmacomechanical thrombolysis tools, such as the Trellis Thrombectomy System (Bacchus Vascular, Santa Clara, CA) and Trellis infusion system (Covidien, Santa Clara, CA), have shown promising results in reducing the thrombus load [21, 45] . These are particularly useful in patients with acute SVCS and with fresh thrombus. In addition, all the patients, except one in a report by Canales et al., had a single trip to the angiography suite [21, 45, 46] . The entire treatment lasted between 38 and 52 minutes [45] . Because they allow faster removal of clot, these devices reduce the need for prolonged administration of thrombolytics, which are fraught with complications [46] .
Complications of Endovascular Treatment
Endovascular treatments for SVCS are safe procedures with a low complication rate occurring in 0%-19% of patients [4] . Complications can be classified as minor or major. Minor complications are related to groin hematoma and local infection at the puncture site. Major complications include stent migration, reocclusion of stents, bleeding, cardiac injury, pulmonary embolism, pulmonary oedema, and pericardial tamponade [4,12e15,18,20,21,24e26,28,61] . The incidence of minor and major complications is 3.2% and 7.8%, respectively [26] . In a recent review, which included 884 malignant SVCS stents placed, there was a mortality rate of 2%. The majority of these were secondary to hemorrhage [24] . There is controversy regarding the routine use of anticoagulants after stenting. In their review of 164 patients, Fagedet et al [13] found that there was no significant relationship between complications and the risk of recurrence in patients on or off long-term anticoagulation therapy. However, in the absence of randomized control trials, the regular use of anticoagulants after stenting remains to the discretion of individual interventionalist.
A feared complication is pericardial tamponade, which can occur secondary to perforation of the intrapericardial portion of the SVC during stent deployment. If unrecognized or not promptly managed, it can be fatal [62] . Hence, appropriate equipment to undertake paracentesis should be available. Although rare, Smith et al [63] recorded a case of delayed fatal pericardial tamponade 6 months after the initial procedure. Stent migration can be avoided by careful stent selection and by ensuring that the stenosis is at the middle of the stent. Wallstents can shorten by 20%-50% necessitating the deployment of further stents [24, 26] . Some researchers have suggested not fully expanding the stent at the waist of the stenosis to prevent migration. However, if migration does occur, various endovascular options, such as snaring the stent directly or balloon-guidewireeassisted snaring of the stent, are available to retrieve stents that have migrated [56, 64] . Stent fractures have also been reported, which is likely to be due to antagonistic movement during cardiac contraction, diaphragmatic movement, and tumour growth into the stent [20, 28] .
Stent restenosis is usually secondary to tumour ingrowth and can lead to occlusion of the stent. Although, this may not pose a major problem in malignant SVCS given the life expectancy of the patient, it becomes relevant in benign SVCS, therefore requiring careful patient selection. In the event of restenosis, repeated endovascular treatment is recommended to reopen the SVC and alleviate the symptoms [25] . A sudden change of pressure distal to the occlusion upon stent deployment is thought to cause a rapid rise in the right atrial pressure secondary to sudden increased venous return. This is associated with a rise in the pulmonary capillary wedge pressure and cardiac output, which can precipitate pulmonary oedema [12, 24] . Patients with preexisting cardiac failure and coronary artery disease are more susceptible. Kee et al [12] reported 1 case of mortality from pulmonary oedema after stenting for SVCS.
Outcome
The average life span of patients with SVCS from a malignancy cause is 6 months [5] . Endovascular treatment in this patient population is most often considered a palliative measure. These are patients who are usually not considered suitable for curative surgery, and, hence, symptom relief is the main goal. Rowell et al [65] found that stents were effective in symptom relief in 95% of cases, with a reocclusion rate of 11% within 3 days to 8 months of insertion. However, the reocclusions were amenable to secondary interventions, which gave a secondary patency rate of 92%. This compares favorably with radiotherapy and chemotherapy, which has patency success rates of 77% and 60%, respectively. These modalities are also associated with recurrence rates of 17-19% with small cell and non-small cell lung cancer [65] . Stents were successful in relieving the obstruction in 81%-100% and were unrelated to the type of stent deployed [24] . Tanigawa et al [23] in their study found that success rate differed between intraluminal tumours and extraluminal compression (50% and 93%, respectively), which also translated to a significant difference in the life expectancy between the 2 groups [23] . Fagedet et al [13] noted less clinical failures in patients without a thrombotic component, because these cases were less complex and more straightforward to undertake.
Reported patency rates among SVCS secondary to benign etiologies are variable. Riley et al [31] in their review reported a 95% success in stenting of benign SVCS. de Gregorio Ariza et al [14] found the primary patency rates for benign causes of SVCS to be 57.1%. After further intervention, the secondary patency rates were recorded as high as 100% over a 31.2 months follow-up period [14] . Sheikh et al [38] reported a primary patency of 79% with a midterm patency rate (primary or assisted primary) of 93% in a cohort of patients followed up for a mean of 28.8 months. But Qanadli et al [39] reported 100% primary patency, with only 1 patient who demonstrated recurrence of symptoms, which was successfully treated with further stent placement [39] . Bornak et al [40] also reported a 100% primary patency rate, which dropped to 67% at 1 year and an assisted patency rate of 100%. Rizvi et al [35] reported the 3-month primary and secondary patency rates as 93% and 96%, respectively, and the cumulative 1-year primary and secondary patency rates as 70% and 96%, respectively, and at 3 years as 44% and 96%, respectively. This variability in reported success and/or patency rates is likely due to the small patient numbers in reported series, leading to reporting bias.
Conclusion
SVCS is due to occlusion or severe stenosis of the SVC either due to malignant neoplasms or benign causes. Although a range of treatment modalities are available, and, although no randomized controlled trials exist, numerous reports in literature have proven endovascular treatment to be one of the safest and most effective techniques to relieve symptoms of SVCS. It has the advantage of having low morbidity and early onset of symptom relief without compromising histologic assessment of possible neoplastic causes. Fortunately, malignant SVCS is rarely a medical emergency, which allows time for careful planning and a multidisciplinary assessment to provide the best possible care. Stenting is the primary modality used with malignant neoplastic causes of SVCS. Benign causes of SVCS are on the rise with increasing use of intravascular devices. Primary angioplasty is favored in such cases, with stenting reserved mostly for frequent recurrences or nonresponsive stenoses. Appropriate patient selection is needed, particularly when stenting is considered.
